Dr. Henry Ji, Sorrento Chairman and CEO, to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento"),
announced today that Dr. Henry Ji, Chairman and CEO, will
participate in the H.C. Wainwright
23rd Global Investment Conference
The conference is being held virtually on September 13-15, 2021.
Dr. Henry Ji, Chairman and CEO of Sorrento, will
provide corporate updates and highlights associated with Sorrento’s
product pipeline in the strategic focus areas of the company:
COVID-19, Cancer and Autoimmune Therapeutics, and Non-Opioid Pain
COVID-19 Product Portfolio
- COVISTIX: COVID-19 Rapid Antigen Detection
Test in commercialization in Mexico with an EUA from COFEPRIS.
Regulatory approval processes in progress in the US, Canada,
Brazil, and WHO EUL (Emergency Use Listing), with active partnering
discussions for global commercialization.
- COVIDROPS (STI-2099):
Intranasal neutralizing antibody (nAb) formulation in Phase 2
trials in UK, US and soon in Mexico for newly diagnosed COVID
patients in an outpatient setting.
- COVI-AMG (STI-2020): Potentially highly
potent/low dose antibody in a 2 minute IV-push in Phase 2 trials
for systemic treatment in an outpatient setting.
- COVISHIELD antibody (STI-9167): Demonstrating
potent in vitro virus neutralization across all currently known
variants of concern (VoCs) and reducing replicating virus in the
lungs of infected transgenic K18 mice (with human ACE2 receptor) to
undetectable levels (following infection by SARS-CoV-2 WA-1 strain
or VoCs including Alpha, Beta, Gamma, Delta, and Lambda).
- MPI-8 and its SAR-Improved Analog (1121):
Small molecule antiviral targeting SARS-CoV-2 main protease,
demonstrating broad-spectrum, potent antiviral activities against
SARS-CoV-2 and all currently known VoCs.
- Multivalent mRNA COVID-19 Vaccine: Elicited a
stronger humoral immune response against Delta VoC as compared to
SARS-CoV-2 intramuscular mRNA vaccine in preclinical studies.
- Recombinant RBD Subunit Vaccine: Demonstrated
strong humoral immune response against WA-1 and Delta VoC in
- Abivertinib: Phase 2 studies for treatment of
acute respiratory distress syndrome (ARDS) in hospitalized COVID
patients in US (96 Pts) and Brazil (400 Pts) are completed.
- COVI-MSC: Phase 2 for ARDS in ICU COVID
patients are ongoing in US and Brazil.
Cancer and Autoimmune Product Portfolio
- Abivertinib: Phase 3 topline data in NSCLC
available Q4 2021.
- Abivertinib: IND for Phase 2 in Prostate
Cancer to be filed Q4 2021.
- PD-L1 antibody: In Phase 3 for SCLC and NDA
submission in China for recurrent or metastatic cervical
- CD38 ADC: In Phase 1 for Amyloidosis and
- CD38 DAR-T: In Phase 1 for Relapsed and
Refractory Multiple Myeloma.
- CD47 antibody: In Phase 1 in solid
- SOFUSA: Lymphatic delivery of Enbrel in Phase
1b in refractory rheumatoid arthritis patients.
Non-Opioid Pain Management Product
- ZTlido: Commercial with strong sales growth
and expanded coverage for up to 65% of lives nationally.
- SP-102: Phase 3/pivotal trial (US) completed
- Resiniferatoxin (RTX): In Phase 2 for
Osteoarthritis pain management.
- RTX: In Phase 2 trial for intractable cancer
pain (pending FDA clearance).
An updated corporate presentation will also be
available at www.sorrentotherapeutics.com
About Sorrento Therapeutics, Inc.
Sorrento is a clinical and commercial stage
biopharmaceutical company developing new therapies to treat cancer,
pain (non-opioid treatments), autoimmune disease and COVID-19.
Sorrento's multimodal, multipronged approach to fighting cancer is
made possible by its extensive immuno-oncology platforms, including
key assets such as fully human antibodies (“G-MAB™ library”),
immuno-cellular therapies (“DAR-T™”), antibody-drug conjugates
(“ADCs”), and oncolytic virus (“Seprehvec™”). Sorrento is also
developing potential antiviral therapies and vaccines against
coronaviruses, including Abivertinib, COVIGUARD™, COVI-AMG™,
COVISHIELD™, COVI-MSC™ and COVIDROPS™; and diagnostic test
solutions, including COVITRACK™, COVISTIX™ and COVITRACE™.
Sorrento's commitment to life-enhancing
therapies for patients is also demonstrated by our effort to
advance a first-in-class (TRPV1 agonist) non-opioid pain management
small molecule, resiniferatoxin (“RTX”), and SP-102 (10 mg,
dexamethasone sodium phosphate viscous gel) (SEMDEXA™), a novel,
viscous gel formulation of a widely used corticosteroid for
epidural injections to treat lumbosacral radicular pain, or
sciatica, and to commercialize ZTlido® (lidocaine topical system)
1.8% for the treatment of post-herpetic neuralgia. RTX has
completed a Phase 1b trial for intractable pain associated with
cancer and a Phase 1b trial in osteoarthritis patients. SEMDEXA is
in a pivotal Phase 3 trial for the treatment of lumbosacral
radicular pain, or sciatica. ZTlido® was approved by the FDA on
February 28, 2018.
For more information visit
This press release and any statements made for
and during any presentation or meeting contain forward-looking
statements related to Sorrento Therapeutics, Inc., under the safe
harbor provisions of Section 21E of the Private Securities
Litigation Reform Act of 1995 and subject to risks and
uncertainties that could cause actual results to differ materially
from those projected. Forward-looking statements include statements
regarding risks and uncertainties that could cause our actual
results to differ materially and adversely from those expressed in
our forward-looking statements, include, but are not limited to:
risks related to Sorrento's and its subsidiaries', affiliates’ and
partners’ technologies and prospects and collaborations with
partners, including, but not limited to risks related to conducting
pre-clinical and clinical studies and seeking regulatory approval
for COVISTIX, COVIDROPS, COVI-AMG, COVISHIELD, MPI-8, Multivalent
mRNA COVID-19 Vaccine, Recombinant RBD Subunit Vaccine,
Abivertinib, COVI-MSC, anti-PD-L1 antibody, anti-CD38 Antibody Drug
Conjugate, CD38 DAR-T, anti-CD47 antibody, the Sofusa Lymphatic
Delivery System, SP-102 and Resiniferatoxin, including the timing
for receipt of any such approval; conducting and receiving results
of clinical trials; clinical development risks, including risks in
the progress, timing, cost, and results of clinical trials and
product development programs; risk of difficulties or delays in
obtaining regulatory approvals; risks that clinical study results
may not meet any or all endpoints of a clinical study and that any
data generated from such studies may not support a regulatory
submission or approval; risks that prior test, study and trial
results may not be replicated in future studies and trials; risks
of manufacturing and supplying drug product; risks related to
leveraging the expertise of its employees, subsidiaries, affiliates
and partners to assist the company in the execution of its COVID-19
therapeutic product candidates strategies; risks related to the
global impact of COVID-19 and other risks that are described in
Sorrento's most recent periodic reports filed with the Securities
and Exchange Commission, including Sorrento's Annual Report on Form
10-K for the year ended December 31, 2020, and subsequent Quarterly
Reports on Form 10-Q filed with the Securities and Exchange
Commission, including the risk factors set forth in those filings.
Investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
release and we undertake no obligation to update any
forward-looking statement in this press release except as required
Media and Investor Relations
ContactAlexis Nahama, DVM (SVP Corporate
Sorrento® and the Sorrento logo are
registered trademarks of Sorrento Therapeutics, Inc.
G-MAB™, DAR-T™, SOFUSA™, MuVAXX™, COVI-AMG™,
COVIDROPS™, COVISHIELD™, Gene-MAb™, COVIDROPS™, COVI-MSC™,
COVITRACK™, COVITRACE™ and COVISTIX™ are trademarks of Sorrento
SEMDEXA™ is a trademark of Semnur
ZTlido® is a registered trademark owned by
Scilex Pharmaceuticals Inc.
All other trademarks are the property of their
©2021 Sorrento Therapeutics, Inc. All Rights
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Dec 2021 to Jan 2022
Sorrento Therapeutics (NASDAQ:SRNE)
Historical Stock Chart
From Jan 2021 to Jan 2022